Abstract-The pro-inflammatory chemokine, monocyte chemoattractant protein-1 (MCP-1), plays a fundamental role in monocyte recruitment and has been implicated as a contributing factor to atherosclerosis. The predominant cell types within the vessel wall-endothelial cells, smooth muscle cells, and macrophages-all contribute to overexpression of MCP-1 in atherosclerotic tissue. In this report we assess the role of MCP-1 expression by leukocytes on lesion progression in a murine model susceptible to atherosclerosis. Bone marrow cells from mice overexpressing a murine MCP-1 transgene on a background of apoE-deficiency or from control mice were transplanted into irradiated apoE-knockout mice. After repopulation of apoE-knockout mice with bone marrow containing the MCP-1 transgene, macrophages expressing the MCP-1 transgene were found in several tissues, including the aorta. Qualitative assessment of atherosclerosis in these mice revealed increased lipid staining, a 3-fold (PϽ0.001) increase in the amount of oxidized lipid, and increased immunostaining for macrophage cell surface markers with anti-F4/80 and anti-CD11b antibodies. There were no differences in plasma lipids, plasma lipoprotein profiles, or body weight between the 2 groups. These results provide the first direct evidence that MCP-1 expression by leukocytes, predominately macrophages, increases the progression of atherosclerosis by increasing both macrophage numbers and oxidized lipid accumulation. 1, 4 Once in the tissue, macrophages potentiate the inflammatory response by producing various inflammatory mediators, such as reactive oxygen species and growth factors, including basic fibroblast growth factor, platelet-derived growth factor, transforming growth factorbeta, and other proinflammatory cytokines and chemokines. 2,5 Monocytes themselves promote additional monocyte adherence and emigration from the vascular space into sites of inflammation. 6, 7 The generation of a murine model in which the apoE gene has been disrupted has provided an important small animal model for the study of atherosclerosis. 8,9 ApoE-deficient mice (apoE-KO) exhibit hypercholesterolemia and develop complex atheromatous lesions similar to those seen in humans. 10,11 These mice develop a full range of lesions, from fatty streaks to raised fibrous plaques, making this model suitable for investigating the pathogenesis of atherosclerosis. To demonstrate the involvement of the macrophage in this process, Smith et al 8 generated a double-mutant mouse by crossing the apoE-KO mouse to the osteopetrotic mouse (op/op), which lacks the expression of macrophage-colony stimulating factor (M-CSF) because of a structural gene mutation. The subsequent M-CSF deficiency in apoE-KO mice resulted in a macrophage deficiency and significant reduction in atherosclerotic lesion size, demonstrating that decreases in circulating monocytes or a reduced tissue macrophage concentration reduces atherosclerosis in this mouse model. 8, 9 In addition to absolute numbers of circulating monocytes, chemotaxis undoubtedly plays an important role in the recruitment and migration of such monocytes to sites of inflammation. Several molecules have been described that have chemotactic activity for monocytes, including N-formylmethionyl-leucyl-phenylalanine, complement fraction C5a, leukotriene B 4 , tumor necrosis factor-␣, 12-hydroxyeicosatetraenoic acid, and monocyte chemoattractant protein-1 (MCP-1). 12 MCP-1, a monomeric polypeptide of molecular weight 9000 to 15 000 Da, is the prototype of the C-C chemokine ␤ subfamily and exhibits its most potent chemotactic activity toward monocytes. 13 In addition to
M onocyte/macrophage cells have an essential role in orchestrating the complex sequence of events involved in the initiation and progression of atherosclerosis. 1 Cells of monocytic origin are present in the developing foam cell lesion, where they engulf lipid and form most of the volume of the fatty streak. 2, 3 This early stage of atherosclerosis is characterized by the focal attachment of monocytes to the endothelium and their subsequent transendothelial migration into the vessel wall. 1, 4 Once in the tissue, macrophages potentiate the inflammatory response by producing various inflammatory mediators, such as reactive oxygen species and growth factors, including basic fibroblast growth factor, platelet-derived growth factor, transforming growth factorbeta, and other proinflammatory cytokines and chemokines. 2, 5 Monocytes themselves promote additional monocyte adherence and emigration from the vascular space into sites of inflammation. 6, 7 The generation of a murine model in which the apoE gene has been disrupted has provided an important small animal model for the study of atherosclerosis. 8, 9 ApoE-deficient mice (apoE-KO) exhibit hypercholesterolemia and develop complex atheromatous lesions similar to those seen in humans. 10, 11 These mice develop a full range of lesions, from fatty streaks to raised fibrous plaques, making this model suitable for investigating the pathogenesis of atherosclerosis. To demonstrate the involvement of the macrophage in this process, Smith et al 8 generated a double-mutant mouse by crossing the apoE-KO mouse to the osteopetrotic mouse (op/op), which lacks the expression of macrophage-colony stimulating factor (M-CSF) because of a structural gene mutation. The subsequent M-CSF deficiency in apoE-KO mice resulted in a macrophage deficiency and significant reduction in atherosclerotic lesion size, demonstrating that decreases in circulating monocytes or a reduced tissue macrophage concentration reduces atherosclerosis in this mouse model. 8, 9 In addition to absolute numbers of circulating monocytes, chemotaxis undoubtedly plays an important role in the recruitment and migration of such monocytes to sites of inflammation. Several molecules have been described that have chemotactic activity for monocytes, including N-formylmethionyl-leucyl-phenylalanine, complement fraction C5a, leukotriene B 4 , tumor necrosis factor-␣, 12-hydroxyeicosatetraenoic acid, and monocyte chemoattractant protein-1 (MCP-1). 12 MCP-1, a monomeric polypeptide of molecular weight 9000 to 15 000 Da, is the prototype of the C-C chemokine ␤ subfamily and exhibits its most potent chemotactic activity toward monocytes. 13 In addition to promoting the transmigration and emigration of circulating monocytes into tissues, MCP-1 exerts various effects on monocytes, including the induction of superoxide anions and expression of the various proinflammatory genes. MCP-1 and its murine homolog JE, which was identified initially as a platelet-derived growth factor-inducible gene, 14 are produced by various cell types within the arterial wall including endothelial cells, smooth muscle cells, and fibroblasts. 15 Increased MCP-1 has been detected in atherosclerotic lesions but not in normal arteries, suggesting its potential role in the recruitment of monocytes and the progression of atherosclerosis. 16 Although MCP-1 has been associated with atherosclerosis as well as several other inflammatory diseases, a cause and effect relationship has been difficult to prove.
Several studies using MCP-1 transgenic mice have suggested that the ability of MCP-1 to elicit monocyte infiltration depends on MCP-1 being expressed at specific sites. In transgenic mice in which MCP-1 overexpression was driven by the mouse mammary tumor virus promoter (MMTV), which directs expression in a broad range of tissues, there were no significant increases in monocyte infiltration in a variety of tissues examined. 17 However, MCP-1 transgenic mice generated using tissue-specific promoters, including the rat insulin II promoter, 18 the myelin basic protein promoter, 19 or the K14 keratin promoter, 20 developed considerable increases in monocyte infiltration in tissues in which MCP-1 expression was detected. Therefore, we sought to develop a model that would selectively address the contribution of MCP-1 expression by macrophages in atherosclerosis.
Circulating monocytes and tissue macrophages within atherosclerotic lesions are originally derived from hematopoietic cells residing in the bone marrow. Thus, bone marrow transplantation provides a means to restrict the expression of a particular gene or transgene to bone marrow-derived cells. 21 Boisvert et al 22 demonstrated that macrophages transplanted from wild-type mouse bone marrow into apoE-KO mice expressed apoE in sufficient quantities to lower plasma lipid levels. Recently, LDL receptor-deficient mice that were irradiated and repopulated with bone marrow cells expressing the interleukin-8 receptor (CXCR-2) yielded smaller lesions than the unmanipulated mice. 23 However, increased lesion size in the CXCR-2 mice with transplant was inferred by comparison with the CXCR-2 mice without transplant. Recently, MCP-1-deficient mice 24 and MCP-1 receptor (CCR2)-deficient mice 25 were shown to have decreased lesion formation in atherosclerotic mice. To determine whether the localized overexpression of MCP-1 by macrophages would result in subsequent amplification of atherosclerosis, irradiated apoE-deficient mice were repopulated with bone marrow cells from MCP-1 transgenic mice and a qualitative and quantitative assessment of atherosclerotic lesions was undertaken.
Methods

Animals
Transgenic mice used in the present study were described previously. 17, 26 Homozygous C57bl/6 apoE-KO mice were established from progenitor stock with a mixed background (129ola ϫ C57bl/6) as described previously. 26 These apoE-KO homozygous mice were backcrossed for 8 generations to C57bl/6 mice and used for atherosclerotic studies. To obtain mice homozygous for both the MMTV-MCP-1 transgene and apoE deficiency, male apoE-KO mice were mated to heterozygous female MMTV/MCP-1(Ϯ) mice. The resulting MMTV-MCP-1(Ϯ)ϫapoE-KO progeny were identified by Southern blot analysis and inbred to produce test donor mice, MMTV MCP-1(ϩ/ϩ)ϫapoE-KO, or control donor mice, MMTV-MCP-1(Ϫ/Ϫ) ϫ apoE-KO. Thus, the strain backgrounds were similar for both donor mice ([FVBX B6]ϫB6) F1. All mice were maintained on a 12-hour light/dark cycle and fed a chow diet.
Bone Marrow Transplantation
At 4 weeks of age, recipient apoE-KO mice were divided into 2 groups. Bone marrow was harvested from femurs and tibias of donor mice as previously described. 22 Bone marrow cells were washed and resuspended in RPMI 1640 (Gibco Life Technologies) supplemented with 2% FBS and heparin (5 U/mL). The cells were administered by tail vein injection 4 hours after lethal irradiation (1000 rad from a cesium gamma source). The recipients received 5ϫ10 6 bone marrow cells (0.3 mL) from either test donor mice, MMTV-MCP-1(ϩ/ ϩ)ϫapoE-KO, or from control donor mice, MMTV-MCP-1(Ϫ/ Ϫ)ϫapoE-KO. These 2 groups of mice are referred to as apoE-KO treated (EO-T) and apoE-KO control (EO-C) mice, respectively. To ensure that the exposure dose was sufficient to ablate the bone marrow, a third group of mice (nϭ6) was irradiated and not given a bone marrow injection. These mice died within 3 days whereas all mice receiving bone marrow survived and appeared in good health.
Tissue Preparation
At 20 weeks of age, mice were fasted for 4 hours, anesthetized with ketamine and xylazine, and sacrificed. Blood was collected in heparin, and bone marrow, liver, lung, spleen, and aorta were removed and snap-frozen in liquid N 2 . The heart was perfused in situ (80 mm Hg) with 10 to 15 mL of PBS, pH 7.4, followed by 4% paraformaldehyde for 3 to 5 minutes. Perfusion-fixed hearts were removed and fixed for an additional 1 to 2 hours in 4% paraformaldehyde followed by infiltration with 30% gum sucrose (1% gum arabic, 30% sucrose in PBS) for 24 hours at 4°C and embedded in either OCT or paraffin.
Peritoneal Macrophages
A subset of mice (nϭ3) were injected intraperitoneally with 1 mL of sterile 6% casein, and peritoneal exudate cells were harvested after 4 days by washing the peritoneal cavity with HBSS (Gibco Laboratories). The peritoneal cells were washed 3 times in HBSS and lysed in TRIzol reagent (Gibco Laboratories), and mRNA was prepared as described below.
Plasma Lipoproteins and Lipids
Separation of plasma lipoproteins using fast protein liquid chromatography (FPLC) was performed as previously described. 27 Total plasma cholesterol and triglycerides were measured using colorimetric methods with commercially available Cholesterol/HP (Boehringer-Mannheim) and Triglyceride-G (Wako Chemicals) kits.
RNA Preparation and Analysis
Frozen tissues were pulverized in liquid N 2 with a mortar and pestle on dry ice, and total RNA was prepared using TRIzol reagent (GIBCO Laboratories). RNA, 8 g for liver, lung, and spleen and 10 g for aorta, was brought up to 20 L in H 2 O and reverse transcribed to cDNA using a random hexamer priming obtained in a cDNA synthesis kit provided by Pharmacia, Biotech Inc. To detect MCP-1 the cDNA was then amplified by PCR using the MCP-1 specific primer 1149 to 5Ј-GCTGGTGAATGAGTAGCAGC-3Ј (nt 208 to 189) in combination with [␥-
32 P]dATP-labeled MCP-1 primer 1148 to 5Ј-GCCAACTCTCACTGAAGCC-3Ј (nt 47 to 66) for the detection of endogenous MCP-1 cDNA and the transgenic RNA or with [␥-32 P]dATP primer 1344 to 5Ј-CGTCTCCGCTCGTCACTTAT-CC-3Ј derived from the transgene MMTV long-terminal repeat (LTR) cap for the unique detection of the transgenic RNA (see Figure 1 ). PCR reactions were carried out for 30 cycles in 50 L with 5 L of cDNA, 100 mol/L dNTPs in PCR buffer (100 mmol/L Tris-HCl, 15 mmol/L MgCl 2 , 500 mmol/L KCl, pH 8.3), 10 pmol of primers, and 2.5 U of native Taq polymerase (Perkin Elmer). PCR amplification was performed as follows: denaturing at 95°C for 2 minutes followed by 30 cycles of 57°C (30 seconds), 72°C (1 minute), and 95°C (1 minute). PCR amplification from 30 cycles results in a 161-bp fragment for the endogenous MCP-1 and a 215-bp fragment for the MCP-1 transgene. The DNA products from the PCR reactions were analyzed on a 6% polyacrylamide gel in TBE buffer, using ␣-32 P-labeled pBR 322 DNA Msp I fragments (New England Biolab, Beverly, Mass) as a molecular weight standard. The polyacrylamide gels were then dried on a slab gel dryer supplied by Enprotech and exposed to X-OMAT x-ray film (Eastman Kodak).
Lesion Analysis
To determine cross-sectional lesion area, hearts were embedded in OCT compound (Baxter) and sectioned at 10 m using a cryostat at Ϫ18°C, as previously described. 27 Cryostat sections were stained with oil red O (Polyscientific) and counterstained with hematoxylin, Gill No. 3 (Sigma Chemical Company). Each section of the aortic valve was evaluated for oil red O staining area by capturing images directly from an RGB camera attached to an Olympus BX-50 light microscope and displaying them on a Trinitron RGB monitor. Image analysis was determined using Optimas 4.1 software (Image Processing Solutions) as described previously. 27 Results are expressed as the average lesion size per section or as the percent of the total cross-sectional vessel wall area (normalϩdiseased area/section, excluding the lumen) stained with oil red O. For each animal, the average of 12 to 16 sections was determined, and data are expressed as lesion size or mean percent lesion area. The percent of the proximal aortic surface covered by lesions was determined using an en face preparation as previously described. 27 Briefly, aortas infiltrated with gum sucrose, as described above, were cleaned of adventitia, and a longitudinal cut was made from the arch down toward the femoral branch. A second longitudinal cut was made between the coronary and carotid arteries in the aortic arch, and the aorta was laid open on a piece of polystyrene. Each aorta was evaluated for lesion area by direct image capture from a CCD camera attached to a copy stand and displayed on a Trinitron monitor. The lesion area was determined in unstained tissue using Optimas 4.1 image analysis. Areas of atherosclerotic plaques in aortas cleaned of adventitia appeared as yellowish-white areas. This area was quantitated by manually setting thresholds for shades of black (background), gray (normal tissue), and white (lesion area).
MCP-1 In Situ Hybridization
Hearts were fixed in 4% paraformaldehyde and embedded in paraffin, and the aortic valves were sectioned at 10 m. To construct riboprobes, the 630-bp EcoRI fragment of the mouse MCP-1 cDNA obtained from ATCC (ATCC 37590) was inserted into pBSII SK ϩ to generate pMMCP-1. The antisense or sense RNA probes were generated by T7 or T3 RNA polymerase with SmaI-or EcoRVlinearized plasmid DNA, respectively, using a DIG/Genius RNA labeling kit (Boehringer Mannheim). After deparaffinization and hydration through a series of graded ethanols, sections were postfixed with 4% paraformaldehyde, and ribosomes were disrupted by treatment with 0.2N HCl for 10 minutes. Sections were treated with 0.5% acetic anhydride to reduce nonspecific background, and deproteinization of sections was performed with 20 g/mL proteinase K for 20 minutes at 55°C. Sections were dehydrated through a series of graded alcohols and dried in chloroform. Dried sections were then heated to 55°C for 30 minutes before adding 10 ng/mL of probe in a hybridization buffer consisting of 2ϫ SSC, 10% dextran sulfate, 0.01% sheared salmon sperm DNA, 0.02% SDS, and 50% formamide. After a 5-minute incubation with the probe at 95°C, the sections were incubated overnight at 62°C. After hybridization, the sections were rinsed twice using 2ϫ SSC at room temperature, followed by two 10-minute washes with 50% formamide in 1ϫ SSC at 55°C. Nonspecific binding was reduced by a 30-minute treatment with 20 g/mL RNase A at 37°C. The slides were incubated with a horseradish peroxidase-conjugated anti-digoxigenin antibody (Boehringer Mannheim) diluted 1:1500 in 0.5% blocking reagent mix (NEN-Life Science) and 1% sheep serum in 100 mmol/L Tris, 150 mmol/L NaCl buffer. The signal was then amplified for 5 minutes using a TSA kit (NEN-Life Science), visualized with 3,3Ј-diaminobenzidine (DAB, Vector Laboratories) and counterstained with hematoxylin, Gill No. 3.
Immunohistochemistry
Paraffin-embedded sections of aortic valves (10 m) were immunostained for MCP-1 with a primary rabbit anti-human polyclonal antibody (Genzyme Diagnostics) in a buffer containing 0.1% saponin at 4°C for 12 hours. The secondary biotinylated antibody, a goat anti-rabbit IgG provided by Jackson Immunoresearch Laboratories, was applied at a dilution of 1:200 for 30 minutes, followed by incubation with horseradish peroxidase-conjugated streptavidin (1:1500, Jackson Immunoresearch Laboratories). An alternative primary rabbit IgG antibody (Jackson Immunoresearch Laboratories) was used as a negative control. Serial cryostat sections (10 m) of the aortic valve were immunostained for macrophages using rat monoclonal antibodies (IgG 2b )against F4/80 (a generous gift from Dr E. Weringer, Pfizer Inc) and CD11b (Pharmingen). An alternative primary rat IgG 2b antibody (Jackson Immunoresearch Laboratories) was used as a negative control. Endogenous biotin and peroxidase activity were blocked by incubating each section with an avidin/ biotin solution (Vector Laboratories), and 0.3% H 2 O 2 in 1% bovine serum, respectively. Sections were then incubated in 3% bovine nonfat milk (Sigma) for 30 minutes at room temperature. Rat anti-mouse F4/80 2b was applied to each section in a dilution of 1:10, and then followed by a biotinylated mouse, anti-rat IgG 2b secondary antibody (1:400, Pharmingen) and incubation with horseradish peroxidase-conjugated streptavidin (1:1500). An alternative primary rat IgG 2b antibody (Pharmingen) was used as a negative control. Rat anti-mouse CD11b 2b (Pharmingen) was used at a dilution of 1:100, followed by the biotinylated mouse anti-rat IgG 2b secondary antibody (1:200, Pharmingen) and incubation with horseradish peroxidaseconjugated streptavidin (1:1500). An alternative primary rat IgG 2b antibody (Pharmingen) was used as a negative control. For immunohistochemical staining of oxidized lipids, a mouse monoclonal antibody against MDA2 (a gift from Dr J. Witztum, Scripps Institute, La Jolla, Calif) was used. Either mouse anti-MDA2 or mouse IgG (Jackson Immunoresearch Laboratories) was applied in a dilution of 1:50, followed by a biotinylated horse anti-mouse secondary antibody and a horseradish peroxidase complex (Vector ABC kit) according to manufacturer's specifications (Vector Laboratories). Antibody binding was visualized with DAB (Vector Laboratories), and all sections were counterstained with hematoxylin, Gill No. 3. Results are expressed as the percent of the total cross-sectional vessel wall area (normalϩdiseased area/section, excluding the lumen) stained with DAB. For each animal, the average of 2 to 3 sections was determined and data are expressed as mean percent.
Statistical Analysis
ANOVA was used to test for statistically significant differences between the groups with regard to treatment, serum lipids, and lesion size. All data are expressed as meansϮSD Figure 1 . Oligonucleotides used for PCR amplification and detection of the MMTV-MCP-1 transgene and murine endogenous MCP-1. First strand cDNA synthesis was performed using a random hexamer priming followed by PCR amplification using oligonucleotides as described in Methods. Primer 1344 in combination with primer 1149 will selectively amplify only transgene RNA, whereas the 1148, 1149 combination will amplify both.
Results
MCP-1 Expression in Recipient Mice
To determine the contribution of macrophage MCP-1 expression in the development of atherosclerosis, apoE-deficient mice were irradiated and repopulated with bone marrow obtained from mice that expressed or lacked an MCP-1 transgene. Successful repopulation of the bone marrow and subsequent differentiation of these cells was confirmed by the demonstration of transgenic MMTV-MCP-1 mRNA in several tissues of EO-T mice including bone marrow (Figure 2 To show that mature macrophages in the EO-T mice were expressing the MCP-1 transgene, mRNA was isolated from macrophages elicited from the peritoneal cavity 16 weeks after transplantation. As shown in Figure 3 , the mRNA corresponding to both the MMTV-MCP-1 transgene and total MCP-1 mRNA were overexpressed in the EO-T mice as compared with the EO-C mice. As the DNA primers used to detect the endogenous MCP-1 also amplify the MCP-1 transgene (Figure 1 ), the absolute levels of endogenous as compared with MMTV-MCP-1 mRNA within the various tissues could not be assessed separately. For a more quantitative assessment, sections of the aortic valve were analyzed for MCP-1 mRNA expression using in situ hybridization. The expression of MCP-1 mRNA and MCP-1 protein in the EO-T mice was markedly increased compared with the EO-C mice ( Figure 4) as evidenced by the differential brown staining with the DAB reagent with the antisense probe, whereas no staining was observed with the sense probe (data not shown). The MCP-1 staining appeared to be localized in cells that had the morphology, as seen under light microscopy, of tissue macrophages and foam cells. By quantifying the amount of positive staining using image analysis, the level of MCP-1 expression (endogenous MCP-1 mRNAϩMMTV-MCP-1 mRNA) was approximately 4-to 5-fold higher in the EO-T mice compared with EO-C (17.1Ϯ2% versus 3.3Ϯ1%, respectively; PϽ0.001, nϭ6). This increased expression resulted in a significant increase in MCP-1 protein as determined by immunostaining for MCP-1 (Table) .
Lesion Area
ApoE-deficient mice spontaneously develop lesions in the aortic valve and throughout the arterial tree. 26 As shown in Figure 5 , lesions were observed throughout the aorta in both EO-T and EO-C mice with lesions being more extensive in the EO-T mice. The increased expression of MCP-1 by leukocytes resulted in a significant increase in the percent of atherosclerotic lesion area (10.4Ϯ0.3% versus 3.7Ϯ0.1%, PϽ0.05, nϭ6) between the EO-T versus EO-C mice, respectively (Table) . When atherosclerotic lesions within serial sections of the aortic valves of EO-T mice were stained for intracellular and extracellular lipid with oil red O ( Figure 6 , top) and quantitative data were expressed as a percentage of the total valve area (Figure 7) , there was also significantly (PϽ0.05) greater percent lesion area compared with EO-C mice (Table) . Corresponding lesion area was increased approximately 50% in the EO-T mice compared with the EO-C mice (106 890Ϯ13 571ϫ10 3 versus 69 253Ϯ20 711ϫ10 3 m 2 , respectively).
Oxidized Lipids
The increase in lesion area in the EO-T mice was paralleled by an even greater increase in the amount of oxidized lipid within the lesion (Table) . Figure 6 , bottom, shows aortic valves from recipient mice stained for lipid with oil red O and immunostained for oxidized LDL with a monoclonal antibody directed against malondialdehyde (MDA) lysineconjugated lipid. By quantifying the amount of lesion area that stained positive for oxidized lipid (eg, stained with DAB), we demonstrated a 3-fold greater amount of lipid oxidation in the EO-T recipients compared with EO-C recipients (Table) . Although in vitro MCP-1 expression is increased by oxidized LDL, the data reported herein demonstrate that MCP-1 expression increases the retention or oxidation of LDL in the vessel wall.
Macrophage Immunostaining
In both groups of recipient mice, lesions at various stages of development could be observed in a single animal. These vascular lesions had a variety of histological appearances ranging from multilayered foam cell deposits to advanced plaques. In the less progressed lesions, macrophage/foam cell deposits were sometimes subendothelial, consisting solely of small groups of lipid-filled cells. In other more progressed lesions, multilayered foam cell deposits were evident. Occasionally, smooth muscle cells were also evident in the intima, and some of these lesions displayed a fibrous cap formation. Although lesions comprised a mixture of cells, immunohistochemical analysis showed a significant increase in the number of cells immunostaining positive for a monocyte/ macrophage-specific surface marker, F4/80 (3.8Ϯ0.4 versus 1.3Ϯ0.2 per lesion area, PϽ0.01) in the EO-T compared with EO-C recipients.
In addition to increased F4/80 staining (Table) , lesions from MCP-1 recipient mice also stained more intensely for the macrophage marker CD11b, the alpha subunit of the ␤2 integrin heterodimer, CD11b/CD18 (Mac-1, CR3 complement receptor type 3). However, unlike F4/80, which showed ) and mRNA (bottom) in serial aortic tissue sections from apoE-KO mice irradiated and repopulated with bone marrow from EO-T or EO-C mice. MCP-1 was detected by immunostaining with a rabbit anti-human MCP-1 polyclonal antibody and DAB staining. In situ hybridization was performed using a 630-bp riboprobe that recognized both the MMTV transgene and endogenous MCP-1 mRNA as described in Methods (magnification ϫ930). ApoE-KO mice were irradiated and repopulated with either bone marrow from control donor mice (EO-C) or mice expressing an MCP-1 transgene (EO-T). Plasma total cholesterol (TC) and triglycerides (TG) were determined enzymatically. Serial frozen 10-m aortic valve sections from each animal (nϭ10 to 12) were obtained and stained for lipid with oil red O, or immunostained with anti-MDA2 (1Ϻ50), rat anti-mouse F4/80 (1Ϻ10), or rat anti-mouse CD11b (1Ϻ100). Hearts embedded in paraffin sections (10 m) (nϭ6/group) were either immunostained for MCP-1 protein with primary rabbit polycolonal antibody (1Ϻ50) or used for in situ hybridization for MCP-1 mRNA determination. The percentage of lesion area within each section showing positive staining was visualized by the amount of DAB-positive staining per total lesion area determined by image analysis. En face preparations of the entire proximal aorta (nϭ6/group) were quantified by image analysis and expressed as a percent area containing raised lesions. Data are expressed as meanϮSD.
Effects of Overexpressing MCP-1 on Plasma Lipids and Atherosclerotic Lesions in ApoE-Deficient Mice
*PϽ0.05, †PϽ0.001, EO-C vs EO-T. uniformed staining of macrophages (Figure 8 ), the CD11b staining appeared to be concentrated in specific areas ( Figure  9 ). As shown in Figure 9 , most of the positive CD11b staining occurred in areas around the necrotic core in cells with the morphologic appearance of macrophages. Together these data are consistent with a proatherogenic role of MCP-1 in enhancing the migration of monocytes into the vessel wall.
Plasma Lipids
Plasma cholesterol and triglyceride levels did not differ between the EO-T and EO-C recipient mice (Table) . Similarly, the distribution of plasma lipoprotein cholesterol, analyzed by FPLC, was also not different between the EO-T and EO-C mice ( Figure 10 ). Thus, the increased lesion area and amount of oxidized lipids could not be attributed to any changes in plasma lipid levels.
Discussion
The objective of our study was to determine whether the overexpression of MCP-1 by macrophages would accelerate the progression and development of atherosclerosis using a well-established animal model system, the apoE-KO mouse. 10, 26 Our results show that expression of MCP-1 by leukocytes increases atherosclerotic lesion size and macrophages in apoE-KO mice. The overexpression of MCP-1 by leukocytes was accomplished by transplantation of bone marrow cells from donor mice expressing a murine MCP-1 transgene into apoE-KO recipient mice. This study is the first to clearly demonstrate that the expression of MCP-1 poten- In another model, MCP-1 was expressed in pancreatic islets under control of the rat insulin promoter. 18 This work also found that the MCP-1-induced leukocyte infiltration was composed almost entirely of F4/80-positive mononuclear cells with the morphological appearance of blood monocytes rather than activated macrophages. In a third study, MCP-1 transgenic mice were generated using an MCP-1 transgene under control of the mouse mammary tumor virus longterminal repeat (MMTV-LTR) promoter. 17 In this model, despite high levels of MCP-1 expression, there was no increase in monocyte infiltrate in any of the expressing organs. The high circulating levels of MCP-1 may have led to desensitization of its receptor on monocytes, rendering them incapable of responding to locally produced MCP-1. 17 To circumvent such nonphysiological plasma MCP-1 concentrations, we limited the expression of MCP-1 to cells derived from bone marrow in the apoE-KO mice. Because macrophages are derived from hematopoietic stem cells, transplanting bone marrow from these animals into apoE-KO mice provided a means to selectively test the effects of macrophage expression on atherosclerotic lesion progression. Previous studies using such a strategy demonstrated that apoE expression by macrophages lowers plasma lipid levels and decreases lesions in the apoE-deficient mouse. 22 In our transplanted animal study, the ability of monocytes to migrate out of the bone marrow and infiltrate various tissues was evident by the detection of the MCP-1 transgene in several organs, including the aorta. Moreover, macrophages elicited from the peritoneal cavity expressed the MCP-1 transgene. Consistent with the role of MCP-1, the increase in lipid-laden lesions in EO-T mice showed much greater staining for both MCP-1 protein and F4/80 as well as a second macrophage marker, CD11b. However, the effect on lesions observed in this study could be a result of increased expression in the vessel wall or a consequence of elevated MCP-1 expression in other tissues. For example, the increased levels of oxidized LDL found in the EO-T animals may have resulted from increased T H 2 cell production of interleukin-4, 28 enhancing the expression of 15-lipoxgenase activity. 29 Recent cell culture studies have shown that the expression of monocyte chemokines MCP-1, macrophage inflammatory protein ␣, and RANTES increased the expression of the ␣ chain of 2 members of the ␤2 family of integrins, CD11a and CD11b. CD11b, one of 2 subunits of the CD11b/CD18 (Mac-1, CR3 receptor) ␤2 integrin, is highly regulated and is expressed maximally in terminally differentiated myeloid cells, including granulocytes, monocytes/macrophages, and polymorphonuclear leukocytes, but is not expressed in lymphoid cells. 30 Because atherosclerotic lesions contain few neutrophils, 31 macrophages are the most likely source for the CD11b in atherosclerotic lesions. It is interesting to note that unlike the uniform staining observed with the F4/80 antibody (Figure 8) , only a small percentage of cells stained positive for CD11b (Figure 9 ). Macrophages that showed the most positive staining for CD11b appeared in necrotic cores of the lesions. Currently, we do not know whether the increases in CD11b staining resulted from an increased number of macrophages or from increased CD11b expression by individual macrophages.
Finally, there is a growing acceptance of a role for oxidatively modified lipoproteins in atherogenesis. 32, 33 All major vascular cell types are capable of oxidizing lipoproteins, and several lines of evidence support the occurrence of oxidized lipoproteins in atherosclerotic lesions in man, as well as the apoE-KO mouse. 34 Oxidized lipoproteins may modulate the expression of genes involved in atherogenesis, eg, mediation of MCP-1 expression by NF-B. 35 However, the specific factors determining lipoprotein oxidation are relatively unknown. In this study, we showed that lesions in the EO-T mice had a significant increase in staining for a lipid oxidation-specific epitope, MDA. 36 MDA is a highly reactive dialdehyde generated during arachidonic acid catabolism and is also known to result from lipid peroxidation that occurs during phagocytosis by monocytes. 37 Whether the increase in MDA staining resulted from increased macrophage numbers in the lesion, or from MCP-1 expression that subsequently potentiated lipid oxidation, is currently being investigated.
As progenitors of tissue macrophages, monocytes play an important role in atherosclerosis, serving as scavengers, secretory cells, and regulators of lymphocyte function. 1 The monocytes that migrate into the subendothelium via cell junctions respond to chemoattractants in the intima or media of the vessel wall. 12 Although MCP-1 has been shown to be expressed in macrophage-rich areas of both human and animal atherosclerotic lesions, 16 ,38,39 the data in this study suggest that MCP-1 expression by macrophages originating from plasma can further promote the infiltration of mono- Figure 10 . FPLC profiles of plasma lipoproteins from apoE-KO mice irradiated and repopulated with bone marrow from EO-T or EO-C mice. Pooled plasma samples from each group (fasted) were separated by FPLC, and the cholesterol content of each fraction was determined enzymatically as described in Methods.
cytes. In addition to acting as a chemoattractant, MCP-1 may further potentiate the inflammatory response by promoting lipid oxidation and integrin expression.
